Compare Stocks → Warning: this could blow your mind (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EXAS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$69.06+3.3%$61.80$56.05▼$100.77$12.54B1.222.03 million shs5.47 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences+3.26%+11.39%+21.37%-6.65%+2.91%Crypto Market Preps For Trillions Worth of Inflows! (Ad)Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online EventMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXASExact Sciences4.5654 of 5 stars3.45.00.04.72.72.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXASExact Sciences2.85Moderate Buy$99.3143.81% UpsideCurrent Analyst RatingsLatest EXAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/22/2024EXASExact SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$100.00 ➝ $90.002/22/2024EXASExact SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/8/2024EXASExact SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/2/2024EXASExact SciencesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$91.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXASExact Sciences$2.50B5.02$0.02 per share3,830.73$17.39 per share3.97Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXASExact Sciences-$204.15M-$1.14N/A∞N/A-8.17%-6.60%-3.20%5/14/2024 (Estimated)Latest EXAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/21/2024Q4 2023EXASExact Sciences-$0.53-$0.27+$0.26-$0.27$638.83 million$646.89 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXASExact SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXASExact Sciences0.742.322.07OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXASExact Sciences88.82%Insider OwnershipCompanyInsider OwnershipEXASExact Sciences1.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEXASExact Sciences6,600181.53 million179.17 millionOptionableEXAS HeadlinesSourceHeadlineExact Sciences gains after data for novel cancer screening testmsn.com - March 28 at 6:32 PMARK Investment Management LLC Has $446.31 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)marketbeat.com - March 28 at 6:39 AMExact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancerbusinesswire.com - March 28 at 6:00 AMExact Sciences Named 2024 Gallup Exceptional Workplace Award Winnerfinance.yahoo.com - March 27 at 12:29 PMWhy Investors Need to Take Advantage of These 2 Medical Stocks Nowzacks.com - March 26 at 9:51 AM3 Growth Stocks to Buy at 52-Week Lows in Marchinvestorplace.com - March 26 at 7:00 AMHow Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%zacks.com - March 25 at 10:56 AMGuru Fundamental Report for EXAS - Benjamin Grahamnasdaq.com - March 23 at 10:49 AMExact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?zacks.com - March 22 at 12:36 PMExact Sciences Corporation (NASDAQ:EXAS) is largely controlled by institutional shareholders who own 89% of the companyfinance.yahoo.com - March 21 at 5:42 PMVanguard Group Inc. Sells 119,581 Shares of Exact Sciences Co. (NASDAQ:EXAS)marketbeat.com - March 20 at 4:56 AMInvestors Buy Large Volume of Exact Sciences Call Options (NASDAQ:EXAS)americanbankingnews.com - March 20 at 1:50 AMExact Sciences Unusual Options Activitybenzinga.com - March 19 at 2:03 PMExact Sciences Target of Unusually Large Options Trading (NASDAQ:EXAS)marketbeat.com - March 19 at 11:20 AMAnalysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)markets.businessinsider.com - March 19 at 9:00 AMGuardant posts data for colon cancer blood test amid push from rivalsfinance.yahoo.com - March 18 at 12:56 PMExact Sciences' (EXAS) BLUE-C Study Results Published in NEJMzacks.com - March 18 at 9:20 AMEXAS Apr 2024 50.000 putfinance.yahoo.com - March 16 at 7:41 AMEXAS Jul 2024 42.500 putfinance.yahoo.com - March 16 at 7:41 AMAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)markets.businessinsider.com - March 15 at 5:37 AMCathie Wood Darling Exact Sciences Rises On Highly Anticipated Colon Cancer Newsfinance.yahoo.com - March 13 at 11:13 PMThe New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Studybusinesswire.com - March 13 at 5:03 PMPolar Capital Holdings Plc Sells 12,001,808 Shares of Exact Sciences Co. (NASDAQ:EXAS)marketbeat.com - March 13 at 8:12 AMBanque Pictet & Cie SA Sells 22,372 Shares of Exact Sciences Co. (NASDAQ:EXAS)marketbeat.com - March 11 at 2:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsExact SciencesNASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.